Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Yosuke Shibata; Go Noguchi; Takahisa Suzuki; Kimito Osaka; Susumu Umemoto; Takeshi Kishida

doi:10.12659/AJCR.932924

06 August 2021: Articles

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Yosuke Shibata ^A* , Go Noguchi ^E , Takahisa Suzuki ^E , Kimito Osaka ^E , Susumu Umemoto ^E , Takeshi Kishida ^E

DOI: 10.12659/AJCR.932924

Am J Case Rep 2021; 22:e932924

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 2. X-rays and CT when interstitial pneumonia appeared. (A) Interstitial pneumonia after 3 cycles of nivolumab treatment. (B) Recurrence of interstitial pneumonia after re-challenge with nivolumab.

Back to the Article

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report

Your Privacy